drug_type
RELEVANT_DRUG
intervention_type
Autologous genetically modified T-cell therapy (CAR T)
drug_description
Autologous, lentiviral-transduced T cells engineered to express CARs targeting both CD19 and CD20 (dual-target CAR T) with CD3ΞΆ and co-stimulatory domains, enabling recognition and elimination of CD19+ and/or CD20+ B-cell malignancies.
nci_thesaurus_concept_id
C180596
nci_thesaurus_preferred_term
Zamtocabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous lentiviral-transduced T cells engineered with a dual CAR targeting CD19 and CD20. Binding to CD19/CD20 on B cells triggers CD3zeta signaling with co-stimulatory domains, inducing T-cell activation, expansion, cytokine release, and cytotoxic killing of malignant B cells; dual targeting is intended to mitigate antigen escape and relapse.
drug_name
MB-CART2019.1
nct_id_drug_ref
NCT06508775